Status: Recruiting
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).
Participants needed: 88
Trial details
Phase: Phase 1Age: 18-55Biological sex: FemaleType: InterventionalSponsor: TerSera Therapeutics LLCUpdated: Jun 3, 2026Locations: 11
Eligibility criteria
Gonadotropin-releasing Hormone (GnRH) treatment-naïve: Female participants aged... [+16]
Postmenopausal: Naturally or surgically postmenopausal (regardless of age). [+28]